Dyslipidemia International Survey-China (DYSIS-China)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01732952 |
|
Recruitment Status : Unknown
Verified November 2012 by Hu Dayi, Chinese Society of Cardiology.
Recruitment status was: Recruiting
First Posted : November 26, 2012
Last Update Posted : November 26, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This cross-sectional, non-interventional, and observational study will assess the lipid profile of patients who have been taking lipid-modifying drugs (i.e., proportion of patients achieving treatment to goal according to national and international lipid management guidelines) during a single visit to their physicians on an outpatient basis in 6 representative geo-economic regions in China: Northeast, North, East, South, Southwest, and Northwest; and within each region, in three tiers of hospitals: tier 3 (primary or teaching hospitals), tier 2 (secondary or city level hospitals), and tier 1 (community hospitals/health centers). The investigators will primarily be cardiologists, endocrinologists, neurologists, gerontologists, internists, or other physicians who are representative of the general population of physicians managing patients with dyslipidemia and/or at high risk for cardiovascular events likely to be treated with lipid-modifying drugs. Demographic data, cardiovascular risk factors, a history of cardiovascular disease and cardiovascular treatments will be documented in a single visit through patient clinical examination and chart review.
DYSIS-China is part of a string of epidemiological studies that share the same master protocol, which has been conducted in different countries mainly in Europe and Canada. The analysis of the pooled studies including overall data and cross-country comparisons is the subject of a distinct protocol.
| Condition or disease |
|---|
| the Prevalence,Lipid Abnormalities, |
| Study Type : | Observational |
| Estimated Enrollment : | 25000 participants |
| Observational Model: | Case-Only |
| Time Perspective: | Cross-Sectional |
| Official Title: | Dyslipidemia International Survey - China |
| Study Start Date : | February 2012 |
| Actual Primary Completion Date : | April 2012 |
| Estimated Study Completion Date : | December 2012 |
| Group/Cohort |
|---|
| regions,hospitals,age, gender, risk levels, comorbidity, |
- the prevalence and types of persistent lipid abnormalities in patients aged > 45 years treated with a lipid-modifying drug [ Time Frame: 6 months ]
- assess patient characteristics, including CV risk levels, in the subsets of patients with persistent lipid abnormalities [ Time Frame: 6months ]
- explore a potential relationship between the persistence of lipid abnormalities and the local known (historical) prevalence of CV morbidity/mortality [ Time Frame: 6months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 45 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
- Patient is an outpatient > 45 years of age
- Patient is currently* treated with a statin
- Patient has a documented fasting lipid profile (> 1 lipid parameter within the last 12 months) performed while on lipid-modifying therapy for at least 3 months
-
Patient agrees to participate in the study by giving informed consent.
- Patient is already being treated with a lipid-modifying drug just before the visit. Patient for whom a lipid-modifying therapy is initiated at the time of the visit must not be included.
Inclusion Criteria:
- Patient is an outpatient > 45 years of age
- Patient is currently* treated with a statin
- Patient has a documented fasting lipid profile (> 1 lipid parameter within the last 12 months) performed while on lipid-modifying therapy for at least 3 months
-
Patient agrees to participate in the study by giving informed consent.
- Patient is already being treated with a lipid-modifying drug just before the visit. Patient for whom a lipid-modifying therapy is initiated at the time of the visit must not be included.
Exclusion Criteria:
1. Patient is currently participating in a clinical trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01732952
| Contact: Hu da yi, Dr. | 8601088324876 | dayi.hu@medmail.com.cn |
| China, Beijing | |
| Peiking University People' Hospital | Recruiting |
| Beijing, Beijing, China, 100044 | |
| Contact: Ding Rong Jing, Dr. 0108688325940 drj2003@sina.com | |
| Sub-Investigator: Ding rong jing, Dr. | |
| Principal Investigator: | Hu da yi, Dr. | Chinese Society of Cardiology |
| Responsible Party: | Hu Dayi, Chinese Society of Cardiology |
| ClinicalTrials.gov Identifier: | NCT01732952 |
| Other Study ID Numbers: |
0000-271-0 |
| First Posted: | November 26, 2012 Key Record Dates |
| Last Update Posted: | November 26, 2012 |
| Last Verified: | November 2012 |
|
the prevalence,lipid abnormalities,CV risks |
|
Congenital Abnormalities Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases |